Zobrazeno 1 - 9
of 9
pro vyhledávání: '"David C. Van Echo"'
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 2, Pp 281-288 (2018)
Case Reports in Oncology
Case Reports in Oncology
Pancreatic cancer is the fourth leading cause of cancer-related death with a median survival of 3–11 months when metastatic. We present a patient with metastatic pancreatic cancer and an exceptional response to initial systemic chemotherapy with FO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76738d443f4e94367f9c6056aea4e15
https://www.karger.com/Article/FullText/489085
https://www.karger.com/Article/FullText/489085
Publikováno v:
Cureus
Gallbladder carcinoma (GBC) is an uncommon malignancy with a high mortality rate. Detecting gallbladder carcinoma in its early stages can be difficult, despite improvements in ultrasound and computed tomography (CT) imaging. Most diagnoses of GBC are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9a93d3274c591caae1e6f71e31e48c3
http://europepmc.org/articles/PMC4792642
http://europepmc.org/articles/PMC4792642
Autor:
George E. Peoples, Constantin N. Baxevanis, Jarrod P. Holmes, Guy T. Clifton, Nathan M. Shumway, Alan K. Sears, M. G. Carmichael, Michael Papamichail, Sathibalan Ponniah, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Sonia A. Perez, Elizabeth A. Mittendorf, David C. Van Echo
Publikováno v:
Expert Opinion on Biological Therapy. 11:1543-1550
Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8+ T-cell-el
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566ce1e29c923a240637835e8b30a9f3
https://doi.org/10.1517/14712598.2011.616889
https://doi.org/10.1517/14712598.2011.616889
Autor:
Jarrod P. Holmes, Timothy J. Vreeland, Sathibalan Ponniah, Alfred F. Trappey, Alan K. Sears, John S. Berry, George E. Peoples, David C. Van Echo, Diane F. Hale, Guy T. Clifton, Ritesh Patil, Elizabeth A. Mittendorf
Publikováno v:
Journal of Clinical Oncology. 31:TPS3126-TPS3126
TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived peptide vaccine. The vaccine was administered in the adjuvant setting to prevent recurrence in breast cancer patients render
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::149952f43ad9930c20ae8a29c5f82e1c
https://doi.org/10.1200/jco.2013.31.15_suppl.tps3126
https://doi.org/10.1200/jco.2013.31.15_suppl.tps3126
Autor:
George E. Peoples, Mohamed Mursal, Athina Zacharia, Sathibalan Ponniah, Yusuf Jama, Anna Chiplis, David C. Van Echo, Elizabeth A. Mittendorf, Alan K. Sears, Guy T. Clifton, Jarrod P. Holmes
Publikováno v:
Cancer Research. 71:LB-413
BACKGROUND: Regulatory T cells (TReg) are elevated in breast cancer patients with the number of TReg cells being inversely associated with clinical outcome. We are conducting a prospective, randomized phase II trial of the HER-2/neu peptide vaccines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1afab2e47cc42c86438dea7eabdadcfd
https://doi.org/10.1158/1538-7445.am2011-lb-413
https://doi.org/10.1158/1538-7445.am2011-lb-413
Autor:
Sathibalan Ponniah, Yusuf Jama, Mark G. Carmichael, Elizabeth A. Mittendorf, Anna Chiplis, Alan K. Sears, Mohamed Mursal, Athina Zacharia, Guy T. Clifton, David C. Van Echo, Jarrod P. Holmes, George E. Peoples
Publikováno v:
Cancer Research. 71:LB-414
BACKGROUND: We are conducting a prospective, randomized, single-blinded phase II trial evaluating the HER-2/neu peptide vaccines AE37 and GP2 in the adjuvant setting to prevent breast cancer recurrence. AE37 is the Ii-Key hybrid of the HER-2/neu pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc4998477aaecd66163ce28f93ce0a42
https://doi.org/10.1158/1538-7445.am2011-lb-414
https://doi.org/10.1158/1538-7445.am2011-lb-414
Autor:
David C. Van Echo, Gauri V. Alvarez, Edwarda M. Buda, Brendan M. Weiss, Daniel L. Cruser, Thomas J. Reid
Publikováno v:
Blood. 104:4532-4532
BACKGROUND. c-kit is a receptor tyrosine kinase for the ligand stem cell factor and a member of the PDGF receptor family. c-kit positivity, as defined by the presence of CD117 by flow cytometry (FC) in > 20% blasts, is detected in up to 90% of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3118d92a5fdf7d0d12efa7cbb4d4f874
https://doi.org/10.1182/blood.v104.11.4532.4532
https://doi.org/10.1182/blood.v104.11.4532.4532
Autor:
Apoe, Ogheneruona, Sin-Ho Jung, Heshan Liu, Seisler, Drew K., Charlamb, Jayne, Zekan, Patricia, Lili X. Wang, Unzeitig, Gary W., Garber, Judy, Marshall, James, Wood, Marie
Publikováno v:
American Journal of Hematology/Oncology; Jul2016, Vol. 12 Issue 7, p4-9, 6p
Autor:
Voorhees, Peter M., Orlowski, Robert Z., Mulkey, Flora, Watson, Peter, Geyer, Susan, Sanford, Ben L., Bennett, Elizabeth, Chanan‐Khan, Asher A., Bloomfield, Clara D., Larson, Richard A.
Publikováno v:
British Journal of Haematology; Nov2015, Vol. 171 Issue 3, p373-377, 5p, 1 Chart, 1 Graph